The Biotech/Pharma Online Pitch event allowed Inura to pitch in front of an online group of renowned international investors.
Last monday our CEO, Rafiq Hussain, and COO, Vanja Ivancevic, successfully presented Inura’s novel therapy to a live audience of renowned international investors at an online Pitch event organized by Hemex AG.
“In all my years working as a physician, I have seen many women who are suffering from this disease, but the current treatment options do not work for everybody,” Rafiq Hussain explained, “patients would not hesitate to test another treatment, and we don’t want to give them another pill, so we are offering them a solution with a novel administration route that actually works” added Vanja.
The online event provided an excellent opportunity to get in contact with different experienced investors. For Inura, it is essential to get investors on board with our unique therapy for OAB. The posssibility of discussing how our solution could significantly improve health and quality of life for women severely affected by OAB is priceless. Overactive bladder (OAB) is a severe chronic condition that can negatively impact patients’ quality of life. At Inura, we are trying to create awareness by seeking to revolutionize women’s health.
Inura Medical AG (“Inura”) is a Swiss start-up company with a clear vision to make a difference in women’s health. Inura’s product is an innovative, first-of-a-kind “urethral ovulum” that utilizes a novel route of drug administration to treat diseases of the bladder and lower urinary tract. Inura’s technology results from decades of work in urology by Professor Grant S. Mulholland, a renowned surgeon, academic, and past President of the American Urology Association. The first indication we are addressing with the ovulum is a chronic disease, named overactive bladder (OAB). More details on https://inuramedical.ch/.
HEMEX AG is a privately-owned Swiss investment and consulting company headquartered close to the Basel global life sciences hub. Its primary focus is to bring innovative drugs, medical devices, and in–vitro diagnostics to the market. HEMEX specializes in supporting early-stage start-ups, offering tailored solutions to accelerate projects into successful and sustainable businesses. Additionally, HEMEX helps and supports start-ups to find non-dilutive and dilutive funding. More at HEMEX.